### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5001</td>
<td>Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination</td>
<td>Teresa Ezponda and Jonathan D. Licht</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5032</td>
<td>Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors</td>
<td>Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher</td>
</tr>
</tbody>
</table>
Table of Contents

PERSONALIZED MEDICINE AND IMAGING
5052 Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Yoshihiro Ohue, Koji Kurose, Yu Mizote, Hirofumi Matsumoto, Yumi Nishio, Midori Isobe, Minoru Fukuda, Akiko Uenaka, Mikio Oka, and Eiichi Nakayama

5064 Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy Janis M. Taube, Alison Klein, Julie R. Brahmer, Haiying Xu, Xiaoyu Pan, Jung H. Kim, Lieping Chen, Drew M. Pardoll, Suzanne L. Topalian, and Robert A. Anders

CANCER THERAPY: PRECLINICAL
5075 Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases Tetsuhiro Kanazawa, Yutaka Hiramatsu, Seiko Iwata, Mohammed Siddiquey, Yoshitaka Sato, Michio Suzuki, Yoshihito Ito, Fumi Goshima, Takayuki Murata, and Hiroshi Kimura

5085 Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer David Karnak, Carl G. Engelke, Leslie A. Parsels, Tasneem Kausar, Dongping Wei, Jordan R. Robertson, Katherine B. Marsh, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, and Meredith A. Morgan

5097 Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma Audrey Lamora, Julie Talbot, Gwenola Bougras, Jérôme Amiaud, Marion Leduc, Julie Chesneau, Julien Taurelle, Verena Stresing, Marie Cécile Le Deley, Marie Françoise Heymann, Dominique Heymann, Françoise Redini, and Franck Verrecchia

BIOLOGY OF HUMAN TUMORS
5113 Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma Chi Young Ok, Jaeyu Chen, Zijian Y. Xu-Monette, Alexandar Tzankov, Ganraj J. Manyam, Ling Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooyung Huh, Xiaoying Zhao, Maurilio Ponzoni, Andrés J.M. Ferreri, Francesco Bertoni, John P. Farnen, Michael B. Moller, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros, and Ken H. Young

5124 Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival Snehal Dabir, Amy Kluge, Adam Kresak, Michael Yang, Pingfu Fu, Bernd Groner, Gary Wildey, and Afshin Dowlati

5133 The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients Yonggang He, Jian Gu, Sara Strom, Christopher J. Logothetis, Jeri Kim, and Xifeng Wu

LETTERS TO THE EDITOR
Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

Correction: A Severe Combined Immunodeficient–hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma

ABOUT THE COVER
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m² cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.